Aires Pharmaceuticals is a technology company.
Aires Pharmaceuticals has raised $20.0M across 1 funding round.
Aires Pharmaceuticals has raised $20.0M in total across 1 funding round.
Aires Pharmaceuticals has raised $20.0M in total across 1 funding round.
Aires Pharmaceuticals's investors include MPM Capital.
Aires Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing therapies for pulmonary disorders, including pulmonary hypertension, cystic fibrosis, pneumonia, and bacterial pulmonary infections. Their flagship product, Aironite, is an inhaled medication designed to deliver nitric oxide for treating these respiratory conditions. The company primarily serves patients with serious pulmonary vascular and infectious diseases, addressing unmet medical needs in respiratory care with innovative inhaled therapies. Aires Pharmaceuticals has demonstrated growth momentum through ongoing clinical trials and collaborations with leading research institutions such as Duke University and Mayo Clinic[1][2][4].
Founded in 2006 and headquartered in San Diego, California, Aires Pharmaceuticals was established to leverage nitric oxide donor technology to treat pulmonary vascular diseases. The founding team brought expertise in pharmaceutical development and pulmonary medicine, with the idea emerging from the need for effective inhaled therapies that can target lung diseases directly. Early pivotal moments include advancing Aironite through clinical stages and forming partnerships with top medical research centers, which have helped validate and propel their therapeutic pipeline[1][4].
Aires Pharmaceuticals rides the trend of precision inhaled therapies targeting pulmonary diseases, a growing area due to increasing prevalence of chronic respiratory conditions and the need for more effective, localized treatments. The timing aligns with advances in drug delivery technology and a heightened focus on respiratory health globally. Market forces such as rising pulmonary disease incidence and demand for innovative therapies favor Aires’ development of inhaled nitric oxide donors. Their work influences the broader pharmaceutical ecosystem by advancing inhaled therapeutic modalities and fostering collaborations between biotech and academic research[1][4].
Looking ahead, Aires Pharmaceuticals is poised to continue clinical development of Aironite and expand its pipeline targeting bacterial pulmonary infections. Trends such as personalized medicine and inhaled drug delivery innovations will shape their trajectory. As they progress toward regulatory approvals and potential commercialization, their influence in pulmonary therapeutics could grow, offering new treatment options for patients with serious lung diseases. Continued partnerships and clinical successes will be critical to their evolution from a clinical-stage company to a commercial pharmaceutical entity[1][4].
Aires Pharmaceuticals has raised $20.0M across 1 funding round. Most recently, it raised $20.0M Series B in November 2010.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2010 | $20.0M Series B | MPM Capital |